SCNIScinai Immunotherapeutics Ltd.

Nasdaq biondvax.com


$ 3.12 $ -1.18 (-28.41 %)    

Friday, 07-Jun-2024 15:34:53 EDT
QQQ $ 462.76 $ -0.41 (-0.09 %)
DIA $ 388.38 $ -0.84 (-0.22 %)
SPY $ 533.54 $ -0.65 (-0.12 %)
TLT $ 91.51 $ -1.71 (-1.83 %)
GLD $ 211.60 $ -7.83 (-3.57 %)
$ 2.97
$ 3.83
$ 0.00 x 0
$ 0.00 x 0
$ 2.71 - $ 3.83
$ 2.56 - $ 18.70
717,993
na
13.79M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2023 03-31-2023 10-Q
2 04-17-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 scinai-immunotherapeutics-cdmo-unit-and-ayana-pharma-signed-a-five-year-master-service-agreement-to-provide-drug-development-and-cgmp-manufacturing-services

Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assu...

 scinai-reports-preclinical-trial-results-of-its-antiil17-vhh-antibody-intends-to-conduct-an-in-vivo-proof-of-concept-animal-study-in-early-2024

The statistically significant results demonstrated the potential for Scinai's anti-IL-17 NanoAbs to noticeably improve psor...

 scinai-immunotherapeutics-ltd-announces-the-publication-following-peer-review-of-an-article-titled-nanobodies-to-multiple-spike-variants-and-inhalation-of-nanobody-containing-aerosols-neutralize-sars-cov-2-in-cell-culture-and-hamsters

Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, address...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION